EP3 Stock Chart & Stats
€3.16
€0.02(0.58%)
At close: 4:00 PM EDT
€3.16
€0.02(0.58%)
Day’s Range― - ―
52-Week Range€1.80 - €4.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€201.54M
Enterprise Value€169.65
Total Cash (Recent Filing)€160.58M
Total Debt (Recent Filing)€12.09M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 10, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding68,968,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.91
Revenue Forecast (FY)€104.58M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Low LeverageA substantial cash balance combined with zero debt gives OraSure financial flexibility to fund product launches, absorb operating volatility, and continue investing without immediate refinancing pressure. This balance-sheet strength is a durable support while the business works toward improved cash generation.
Regulatory Milestones Expand Product PotentialClearance for Colli-Pee and authorization for Ebola 2.0 expand OraSure’s commercial product set and address significant infectious-disease testing needs. These milestones can support future revenue growth through launches, public-health programs, and broader customer adoption.
Sequential Recovery And Margin ImprovementSequential growth across the business, together with improving gross margin, indicates that demand and operating execution are recovering from recent weakness. Reiterated 2026 growth guidance and planned efficiency benefits provide a foundation for improving earnings quality over the next several quarters.
Bears Say
Severe Revenue And Profitability DeteriorationThe sharp contraction in revenue and deeply negative operating and net margins show that OraSure’s current expense base is not aligned with its reduced sales level. Unless demand and cost structure improve, sustained losses could constrain investment capacity and weaken the durability of the recovery.
Meaningful Ongoing Cash BurnCurrent cash consumption is a material financial weakness despite the company’s strong liquidity. Negative operating and free cash flow increase dependence on the existing cash reserve and make the expected path to operating cash-flow breakeven important for preserving strategic flexibility.
IntelliQ Regulatory DelayThe IntelliQ setback delays a potentially important rapid molecular testing opportunity and removes a previously expected 2026 U.S. launch. Uncertain resubmission timing extends development risk, postpones possible revenue contribution, and makes the company more reliant on other product launches.
Orasure Technologies News
EP3 FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was €1.80 and its highest was €4.00 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is €201.54M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Nov 10, 2026 which is in 54 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on Aug 05, 2026. The company reported €0.078 earnings per share for the quarter, beating the consensus estimate of -€0.234 by €0.312.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.2.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 68,968,630 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of €0.078 in its last earnings report, beating expectations of -€0.234. Following the earnings report the stock price went down -3.955%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in DE:EP3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Orasure Technologies
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
EP3 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.View all DE:EP3 earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―







